SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Blair Rainer | President & CEO, Director | 2026-08-21 | Open-market sell | 11307 | $2.5M |
| Blair Rainer | President & CEO, Director | 2026-08-21 | Open-market sell | 39193 | $8.6M |
| Blair Rainer | President & CEO, Director | 2026-08-21 | Open-market sell | 7755 | $1.7M |
| Gutierrez-Ramos Jose-Carlos | SVP, Chief Science Officer | 2026-08-04 | Grant/award | 13477 | $0 |
| Milosevich Gregory M | Executive Vice President | 2026-08-04 | Grant/award | 15402 | $0 |
| RALES MITCHELL P | Chairman of Exec. Committee, Director | 2026-08-04 | Grant/award | 500000 | $0 |
| RALES STEVEN M | Chairman, Director | 2026-08-04 | Grant/award | 500000 | $0 |
| Riley Christopher Paul | Executive Vice President | 2026-08-04 | Grant/award | 41072 | $0 |
| Bouda Christopher | VP, Chief Accounting Officer | 2026-07-15 | Tax withholding | 60 | $12K |
| FILLER LINDA | Director | 2026-07-15 | Option exercise | 3298 | $237K |
| FILLER LINDA | Director | 2026-07-15 | Tax withholding | 1181 | $237K |
| Zerhouni Elias A. | Director | 2026-07-15 | Option exercise | 3298 | $237K |
| Zerhouni Elias A. | Director | 2026-07-15 | Tax withholding | 1181 | $237K |
| Couchara Georgeann | SVP, Human Resources | 2026-05-15 | Tax withholding | 281 | $45K |
| Dewan Feroz | Director | 2026-05-15 | Grant/award | 680 | $0 |
| FILLER LINDA | Director | 2026-05-15 | Grant/award | 680 | $0 |
| Lamanna Charles W | Director | 2026-05-15 | Grant/award | 680 | $0 |
| List Teri | Director | 2026-05-15 | Grant/award | 680 | $0 |
| SPOON ALAN G | Director | 2026-05-15 | Grant/award | 680 | $0 |
| Sanders A Shane | Director | 2026-05-15 | Grant/award | 680 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Debt load rose 15% to $18.4B with Masimo acquisition financing adding concrete near-term leverage risk, while tariff escalation, AI/cybersecurity exposure, and new regulatory headwinds (FDA staffing cuts, ethylene oxide/PFAS) collectively broaden the risk profile across multiple dimensions. M&A execution risk moved from hypothetical to demonstrated, with the company explicitly acknowledging failure to sustain historical acquisition rates alongside a material pending transaction. The sole offset — removal of restructuring disclosure — is modest against the breadth of worsening.
4 company-specific · 1 eased/removed · 4 common-mode
Outstanding debt increased 15% ($16.0B to $18.4B). New disclosure of pending Masimo acquisition financing adds concrete debt risk. Available borrowing capacity slightly decreased.
Financial and Tax Risks From time to time our outstanding debt has increased significantly as a result of acquisitions, and we expect to incur additional debt in the future. Our existing and future…
Company now explicitly discloses failure to meet historical acquisition rates over past years and ongoing inability to do so, escalating from hypothetical risk to demonstrated operational shortfall.
Acquisition, Divestiture and Investment Risks Failing to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term…
Pending Masimo acquisition explicitly called out, signaling a material transaction with specific integration and financial risks now in play.
Our acquisition of businesses, investments, joint ventures and other strategic relationships can negatively impact our business and financial statements. As part of our business strategy, we acquire…
New disclosure of FDA staffing reductions and government spending cuts creating risk of delayed regulatory approvals and inspections—a substantive operational risk.
Certain of our businesses are subject to extensive regulation by the FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the…
Removal of explicit restructuring risk disclosure signals completion or de-escalation of material cost reduction activities previously flagged as ongoing.
Our restructuring actions and other cost reduction efforts can have long-term adverse effects on our business and financial statements. In the past, we have implemented significant restructuring and…
Tariff risk escalated materially: new Supreme Court ruling, retaliatory cycles, concrete cost impacts, margin pressure, supply chain disruption, and demand risk now explicitly disclosed.
Legal, Regulatory, Compliance and Reputational Risks Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can…
Revised language escalates AI risks: adds "premature" deployment, specifies IP/privilege loss, confidential data disclosure, and third-party IP infringement as concrete harms.
Uncertainties with respect to the development, deployment, and use of AI in our business and products may result in harm to our business and reputation. We are in the early stages of incorporating…
New disclosures of AI-intensified cybersecurity risks, connected medical devices, customer patch management vulnerabilities, and evolving data privacy enforcement focus on AI/biometrics escalate risk profile materially.
Operational Risks Significant disruptions in, or breaches in security of, our IT systems or data or violation of data privacy laws can adversely affect our business and financial statements. We rely…
New disclosure of evolving regulatory requirements on ethylene oxides and PFAS impacting operations and supply chain, escalating compliance risk.
Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our business and financial statements.…
Julie Sawyer Montgomery was appointed as President and Chief Executive Officer of Danaher, effective October 1, 2026, and was also appointed to the Board and three Board committees, representing a major leadership succession at the company.
View raw filing on EDGAR →The Compensation Committee approved special equity grants to Steven M. Rales and Mitchell P. Rales on July 31, 2026, comprising non-qualified stock options (1,000,000 shares each) and restricted stock units (500,000 shares each) with four- to five-year vesting as part of a Long-Term Growth Program.
View raw filing on EDGAR →Danaher issued a press release on July 21, 2026 announcing financial results for the quarter ended June 26, 2026, disclosing net earnings of $870 million ($1.23 per diluted share, up 60% YoY), revenues of $6.3 billion (up 5.5% YoY), and raising full-year 2026 adjusted EPS guidance to $8.45–$8.60. This is a standard quarterly earnings release filed under Item 2.02 with consolidated financial statements and forward-looking guidance.
View raw filing on EDGAR →Danaher completed a material private placement of CHF 2.26+ billion in senior unsecured notes across seven series with maturities from 2031 to 2056, with proceeds to be used for general corporate purposes including acquisitions and share repurchases.
View raw filing on EDGAR →